RL
Relay Therapeutics, Inc.
RLAY · NASDAQ
$18.84 -0.69% (-$0.13)
1M -8.59%
Market Cap $4.13B
P/E Ratio -
Div. Yield -
ROE 42.27%
Piotroski F-Score Weak
3/9Valuation
21 /100
Expensive P/S 398.90x
P/B 4.64x
P/E N/A
Growth
78 /100
Growing Rev. growth 123.20%
Book val. growth 15.81%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 566.59%
FCF margin 2,050.29%
Net margin 2,763.64%
Quality
0 /100
Poor ROIC 33.72%
Asset turnover 0.01x
ROE 42.27%
Debt
100 /100
Low Debt/Equity 0.03x
Current ratio 18.27x
Int. coverage N/A
Stability
31 /100
Unstable Beta 1.70x
Profitable years 0
Rev. volatility 1,014.00%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about RLAY
Online
About the company
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery.
Sector
Healthcare
Industry
Biotechnology
CEO
Sanjiv K. Patel
Employees
202
Headquarters
Cambridge
Upcoming events
05 NOV
Earnings
Upcoming earnings report